|
Variable
|
Patients with device malfunction n = 15
|
Patients without device malfunction n = 7
|
p-value
|
|---|
|
Age (years)
|
56 (50; 68)
|
64 (61; 64)
|
0.45
|
|
Gender (female)
|
3 (20)
|
1 (14%)
|
0.62
|
|
BSA (m2)
|
1.96 (1.76; 2.06)
|
1.95 (1.73; 2.22)
|
0.54
|
|
eGFR (mL/min/1.73 m2)
|
61 (51; 80)
|
36 (29; 44)
|
0.001
|
|
EF (%)
|
15 (15; 20)
|
20 (15;30)
|
0.16
|
|
Type of cardiomyopathy:
| | |
0.44
|
|
Idiopathic
|
6 (40)
|
4 (57)
| |
|
Ischemic
|
7 (46)
|
2 (29)
|
|
Drug/alcohol abuse
|
1 (7)
|
1 (14)
|
|
Other causes
|
1 (7)
|
0
|
|
Indication for HVAD® therapy:
| | |
0.44
|
|
DT
|
5 (34)
|
2 (29)
| |
|
BTT
|
2 (13)
|
2 (29)
|
|
BTD
|
6 (40)
|
1 (14)
|
|
BTD/DT
|
0
|
1 (14)
|
|
BTD/BTT
|
2 (13)
|
1 (14)
|
- The baseline characteristics of the study patients at the time of implantation, comparing those who did (n = 15) vs. did not (n = 7) experience any device malfunction during follow-up
- Abbreviations: HVAD® HeartWare® left ventricular assost system, BSA Body surface area, eGFR Estimated glomerular filtration rate using the CKD-EPI (chronic kidney disease epidemiology collaboration), DT Destination therapy, BTT = Bridge to transplantation, BTD Bridge to decision, EF Ejection fraction
- Data are presented as median (interquartile range) or n (%)
